| Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 | Sep'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Total revenues | |||||||||
5,389 | 3,903 | 4,751 | - | - | - | - | - | - | - |
Product revenues | |||||||||
- | - | - | 2,538 | 5,435 | - | - | - | - | - |
Service revenues | |||||||||
- | - | - | 1,648 | 3,572 | - | - | - | - | - |
Total revenues | |||||||||
- | - | - | 4,186 | 9,008 | 2,721 | 2,036 | 1,854 | 968 | 519 |
Cost of revenues | |||||||||
877 | 1,206 | 1,077 | 1,170 | 384 | - | - | - | - | - |
Operating expenses: | |||||||||
Selling, general and administrative | |||||||||
10,278 | 11,043 | 13,324 | 10,808 | 13,410 | 13,249 | 11,198 | 7,615 | 8,388 | 7,189 |
Research and development | |||||||||
2,967 | 2,751 | 2,282 | 3,700 | 2,577 | 1,300 | 692 | 432 | 268 | 75 |
Depreciation and amortization | |||||||||
390 | 547 | 887 | 706 | 490 | 442 | 321 | 313 | 367 | 371 |
Total operating expenses | |||||||||
13,635 | 14,342 | 16,494 | 15,215 | 16,478 | 14,992 | 12,212 | 8,362 | 9,025 | 7,636 |
LOSS FROM OPERATIONS | |||||||||
-9,124 | -11,646 | -12,820 | -12,199 | -7,853 | -12,271 | -10,175 | -6,507 | -8,056 | -7,117 |
Other (expense) income: | |||||||||
Interest expense (including related parties interest of $25,840 and $49,310 for the three and six months ended March 31, 2019, respectively) | |||||||||
-162 | -9 | 2 | 11 | -23 | -11 | 1 | -643 | - | - |
Interest income (expense), net | |||||||||
- | - | - | - | - | - | - | - | 2,458 | 792 |
Other expense, net | |||||||||
-43 | -37 | -38 | 12 | -28 | 123 | -3 | - | - | - |
Loss on extinguishment of debt | |||||||||
-1,260 | 0 | - | - | - | - | - | - | - | - |
Unrealized gain on change in fair value of secured convertible notes payable | |||||||||
1,972 | 0 | - | - | - | - | - | - | - | - |
Loss on conversion of Promissory notes | |||||||||
- | - | - | - | 980 | - | - | - | - | - |
Loss on change in fair value of warrant liability | |||||||||
- | - | - | - | 2,994 | - | - | - | - | - |
Loss on change in fair value of warrant liability | |||||||||
- | - | - | - | - | -908 | -7,508 | - | - | - |
Loss before provision for income taxes | |||||||||
-8,617 | -11,692 | -12,855 | -12,175 | -11,881 | -13,066 | -17,686 | -7,150 | -10,515 | -7,909 |
Provision for income taxes | |||||||||
15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NET LOSS | |||||||||
-8,632 | -11,692 | - | - | - | - | - | - | - | - |
Less: Net (income) loss attributable to noncontrolling interest | |||||||||
-9 | 0 | - | - | - | - | - | - | - | - |
NET LOSS attributable to Applied DNA Sciences, Inc. | |||||||||
-8,623 | -11,692 | -12,855 | -12,175 | -11,881 | -13,066 | -17,686 | -7,150 | -10,515 | -7,909 |
Deemed dividend related to warrant modifications | |||||||||
-309 | 0 | - | - | - | - | - | - | - | - |
NET LOSS applicable to common stockholders | |||||||||
-8,932 | -11,692 | - | - | - | - | - | - | - | - |
Net loss per share applicable to common stockholders-basic and diluted | |||||||||
-9.69 | -15.86 | -0.49 | -0.51 | -0.63 | -0.97 | -1.51 | -0.74 | -0.03 | -0.03 |
Weighted average shares outstanding-basic and diluted (in shares) | |||||||||
921 | 737 | 26,378 | 23,693 | 18,938 | 13,515 | 11,730 | 9,601 | 376,833 | - |
Weighted average shares outstanding-Basic and fully diluted (in shares) | |||||||||
- | - | - | - | - | - | - | - | - | 300,352 |
Product | |||||||||
Total revenues | |||||||||
2,136 | 1,827 | - | - | - | - | - | - | - | - |
Service | |||||||||
Total revenues | |||||||||
3,253 | 2,075 | - | - | - | - | - | - | - | - |